Mass­a­chu­setts judge dis­miss­es law­suit against Bio­gen over failed launch of Alzheimer's drug Aduhelm

A Mass­a­chu­setts fed­er­al judge on Wednes­day dis­missed a class ac­tion law­suit filed by in­vestors against Bio­gen and sev­er­al of its cur­rent and for­mer ex­ec­u­tives over the com­pa­ny’s failed Alzheimer’s drug, Aduhelm (ad­u­canum­ab).

The in­vestors ar­gued that Bio­gen’s con­tact with the FDA was un­law­ful and that the com­pa­ny made 25 false and mis­lead­ing state­ments, in­clud­ing state­ments about the roll­out and price of the drug.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER